In this exploratory analysis of a randomized controlled trial, we found that dynamic changes in simple laboratory-based markers such as prostate-specific antigen (PSA) could be used to predict survival in patients with metastatic prostate cancer that is sensitive to hormonal manipulation. Here, KLK3 is linked to metastatic prostate carcinoma.